{"nctId":"NCT00231777","briefTitle":"A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)","startDateStruct":{"date":"2005-07"},"conditions":["Post-Operative Nausea and Vomiting"],"count":216,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: MK0517"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: ondansetron"]}],"interventions":[{"name":"Comparator: MK0517","otherNames":[]},{"name":"Comparator: ondansetron","otherNames":["Zofran"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Open abdominal surgery requiring 24 hour hospital stay\n* General anesthesia\n* Post-operative opioids\n* ASA status of I-III\n\nExclusion Criteria:\n\n* Patient exhibits evidence of any clinically significant respiratory, metabolic, hepatic, renal dysfunction, or cardiovascular condition or congestive heart failure (CHF)\n* Morbid obesity\n* Patient is mentally incapacitated or has a significant emotional or psychiatric disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Clinical Adverse Experiences (CAEs)","description":"An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Laboratory Adverse Experiences (LAEs)","description":"A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Drug-related CAEs","description":"Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Serious CAEs","description":"Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":167},"commonTop":["Nausea","Pruritus","Constipation","Headache","Hypotension"]}}}